41457-34-5Relevant academic research and scientific papers
Montmorillonite K10 catalyzed highly regioselective azidolysis of epoxides: A short and efficient synthesis of phenylglycine
Ch Ghosh, Keshab,Banerjee, Isita,Sinha, Surajit
, p. 2923 - 2934 (2018)
A series of β‐hydroxyazides were effectively synthesized from the regioselective ring opening of epoxides by sodium azide using montmorillonite K10 as a novel heterogeneous catalyst in aqueous acetonitrile in good to excellent yields. The utility of this method has been demonstrated by achieving a short synthesis of phenylglycine in 33.5% overall yield.
Nonracemic Dimethylphenyl Glycerol Ethers in the Synthesis of Physiologically Active Aminopropanols
Bredikhina,Kurenkov,Bredikhin
, p. 837 - 844 (2019/08/02)
Six regioisomeric nonracemic dimethylphenyl glycerol ethers were synthesized by asymmetric dihydroxylation of the corresponding allyl dimethylphenyl ethers. The enantioselectivity of the reaction with o-methyl derivatives was lower (down to 34% ee) than with m-methylphenyl ethers (up to 86% ee). Enantiomeric 3-(3,4-dimethylphenoxy)propane-1,2-diols were used to obtain enantiomerically pure physiologically active amino alcohols and their derivatives.
Regioselective ring-opening of epoxides by carbazole: A direct preparation of novel N-(β-hydroxyalkyl)carbazoles
Soltani Rad, Mohammad Navid,Behrouz, Somayeh,Ahrari, Samira
, p. 137 - 140 (2016/04/20)
The influence of various parameters including solvent, base and temperature on the reaction between carbazole and epoxides was studied This led to the development of a regioselective ring-opening of epoxides by the potassium salt of carbazole in DMSO at 100 °C which is a straightforward way to prepare new N-(β-hydroxyalkyl)carbazoles in good to excellent yields. Fifteen new compounds are described.
THERAPEUTIC COMPOUNDS
-
Paragraph 00118; 00120, (2015/02/02)
The present invention relates to therapeutic compounds useful for the treatment of neurodegenerative and neuromuscular diseases and/or triplet repeat diseases (e.g. Friedreich's ataxia). The compounds have the structural formula I shown below: wherein Q, X, p, R1, q, R3 and R4 are as defined herein. The present invention also relates to pharmaceutical compositions comprising the compounds defined herein, the use of these compositions for the treatment of neurodegenerative and neuromuscular diseases and/or triplet repeat diseases (e.g. Friedreich's ataxia), and to processes for the preparation of the pharmaceutical compositions defined herein.
